Connecting Scientific Innovation with Commercial Strategy

Life Sciences Review | Thursday, September 17, 2026

The life sciences sector rarely has the luxury of making decisions in isolation. A promising molecule can encounter regulatory uncertainty. A successful clinical program can face commercial access challenges. A medical technology company can develop an innovative product yet struggle to build a sustainable route to market. Each decision carries scientific, financial and regulatory consequences.

That complexity has expanded the role of life sciences consulting. What was once concentrated around strategy and management advice now reaches across research and development, clinical development, regulatory affairs, manufacturing, market access, commercial strategy, technology and transactions.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Life Sciences Outlook found that more than 75 percent of surveyed biopharma and medtech executives were confident about their own organizations’ financial outlook, while only 41 percent were optimistic about the global economy. The contrast captures the environment in which consulting firms are increasingly expected to help companies make precise decisions amid uncertainty.

Strategy Must Connect Science With Commercial Reality

Life sciences strategy begins well before a product reaches the market. Companies need to determine which therapeutic areas deserve investment, which assets should advance and where partnerships or acquisitions can strengthen the pipeline.

Consultants can bring an external view to these decisions by combining market intelligence, portfolio analysis, competitive research and financial modeling. For established pharmaceutical companies, this can mean reviewing large portfolios for opportunities to concentrate capital on differentiated assets. For emerging biotechnology companies, the priorities may involve preparing for a funding round, licensing discussions or a pivotal development milestone.

The renewed interest in transactions adds another layer. Reported that 45 percent of surveyed biopharma executives and 51 percent of medtech executives viewed mergers and acquisitions as a near-term strategic priority.

Clinical Development Faces Greater Pressure

Clinical development remains one of the areas where specialist advice can have a direct effect on timelines and investment decisions. Trial design, patient recruitment, site selection, data strategy and regulatory interaction all influence whether a development program progresses efficiently.

Regulators are also examining ways to modernize development. In 2026, the U.S. Food and Drug Administration announced initiatives under Operation TrialBlazer intended to accelerate and modernize clinical research from the investigational stage through late-stage trials. The agency has also issued draft guidance supporting greater use of Bayesian statistical methodologies in clinical trials.

“ The direction of the sector suggests that life sciences consulting will increasingly be judged by the quality of decisions it enables rather than the volume of recommendations it produces. “

These developments create demand for consultants who understand both scientific methodology and the practical requirements of program execution. The value is not simply in producing another strategy document. It lies in translating regulatory expectations and scientific possibilities into decisions that development teams can act upon.

Regulatory Complexity Shapes Market Decisions

Regulatory affairs has become inseparable from business planning. A product’s development pathway, evidence requirements, labeling strategy and approval timeline can affect investment decisions long before a submission is made.

Life sciences consultants increasingly work across regulatory and commercial functions rather than treating them as separate disciplines. Market entry plans, pricing assumptions and launch sequencing may need to account for differences between jurisdictions and changing reimbursement environments.

This matters particularly for companies operating across multiple markets. A strategy that works in one country may require substantial modification elsewhere because approval pathways, payer expectations, healthcare infrastructure and evidence requirements differ.

Technology Needs a Business Case

Digital transformation has become a significant part of consulting engagements across the sector, but technology adoption alone does not guarantee value. Life sciences organizations have invested heavily in data platforms, automation, advanced analytics and artificial intelligence. The more difficult question is where these investments produce measurable improvements.

Research found that life sciences leaders were increasingly focused on productivity, commercial performance, investment discipline, partnerships and measurable AI deployment. The research also noted a gap between AI adoption and the ability to capture its value.

That gap creates a practical role for consultants. Instead of recommending technology in isolation, firms can help identify suitable use cases, redesign workflows, establish governance and define performance measures. In research, this might involve improving data analysis. In commercial operations, it could involve better customer insights. In manufacturing, the focus may be quality, planning or supply visibility.

From Cost Management to Operating Models

Cost pressure is also changing consulting priorities. Life sciences companies must protect research investment while improving productivity elsewhere. Manufacturing networks, procurement structures, shared services and commercial organizations are therefore receiving closer scrutiny.

For biopharma companies, improving R&D productivity has become particularly important. Deloitte reported that 41 percent of surveyed biopharma executives identified it as their top priority for managing costs.

Consulting assignments in this area increasingly examine how work is organized rather than simply where expenses can be reduced. A more effective operating model may clarify decision rights, remove duplicated processes, improve collaboration between functions or determine which activities should remain internal.

Specialization Becomes a Competitive Advantage

The strongest life sciences consulting engagements tend to depend on industry knowledge. Pharmaceutical and biotechnology companies require advisors who understand development economics, regulatory pathways, clinical operations and intellectual property. Medtech organizations face a different combination of product development, quality systems, reimbursement and provider-market dynamics.

That specialization is reflected in the consulting market. PwC, for example, was recognized by IDC as a Leader in Worldwide Life Sciences R&D Strategic Consulting Services in 2026, highlighting multidisciplinary capabilities spanning strategy, transactions, technology and clinical trial execution.

The direction of the sector suggests that life sciences consulting will increasingly be judged by the quality of decisions it enables rather than the volume of recommendations it produces. Scientific innovation remains the foundation, but successful commercialization requires disciplined choices around capital, evidence, regulation, technology and market access.

Consulting firms that can connect those dimensions without losing sight of the science will occupy an important position in the industry’s next phase. For pharmaceutical, biotechnology and medtech leaders, the most useful external partner may be the one capable of turning complex information into a clear course of action.

More in News

Europe's Evolving Research Landscape and Digital Innovation in Clinical Trials

Clinical research programs are placing greater emphasis on patient-centred execution, reliable data collection and smoother coordination between sponsors, investigators and research sites. Clinical trials services are helping life sciences companies manage these priorities by improving patient recruitment, strengthening trial monitoring, supporting accurate data management and coordinating activities across geographically distributed studies. In Europe, service providers are assisting sponsors in conducting multicountry clinical trials in addition to following consistent study practices in all the sites involved. This coordinated approach can shorten administrative delays, improve participant engagement, strengthen data quality and help research teams make more informed decisions as therapies progress through development. Evolving Clinical Trial Landscape Clinical development is moving toward study models that can accommodate complex protocols, specialised patient populations and wider geographic reach. Sponsors are increasingly considering adaptive trial designs, decentralised elements, hybrid models and real-world evidence to generate useful insights throughout development. Greater patient involvement in study planning is influencing visit schedules, participation requirements and trial experiences, creating demand for more flexible clinical trial services. The growing focus on precision medicine, biomarker-driven research, rare diseases and advanced biologic therapies is changing the structure of clinical programs. Such studies often require disease-specific expertise, focused recruitment strategies and carefully selected research sites. Europe remains an important region for multinational development programs, giving clinical trials services an expanding role in connecting appropriate capabilities with increasingly focused study requirements. Patient expectations are shaping how clinical research is conducted. Remote consultations, electronic consent, home-based activities and wearable devices are gaining relevance in suitable studies, offering participants greater convenience during trial involvement. These approaches are encouraging sponsors to consider study models that balance accessibility, participant experience, scientific rigour and efficient evidence generation. Regulatory and Operational Challenges Clinical research teams have to operate in a challenging compliance setting since there may be some differences in clinical trial demands depending on location, treatment domain and development phase. Variations in documentation standards, ethics review procedures, informed consent expectations and reporting obligations can create additional administrative work. Operational bottlenecks can emerge when studies involve numerous stakeholders, specialised procedures and tightly sequenced activities. Clinical trials services can help address this complexity through structured compliance processes, jurisdiction-specific expertise and regular review of study documentation, helping research teams maintain alignment as requirements change. Delays in site activation, inconsistent execution of study procedures, limited availability of qualified personnel and supply-related disruptions can affect timelines. Clear responsibility mapping, standardised workflows, staff training and proactive issue tracking can give trial teams greater control over these operational pressures. Europe has more concerns for sponsors who conduct trials in many national environments, where there could be differences in ethical procedures, language requirements, contracting practices and other expectations on their end. Regional expertise, centralised oversight, localised documentation support and clearly defined communication channels can help clinical trials services manage these differences while keeping study activities aligned with the broader research plan. Technological Advancements and Future Outlook AI is becoming increasingly relevant to clinical research, particularly in areas that involve large volumes of complex information. Machine learning can support patient matching, identify patterns within study data, and assist researchers in assessing potential risks. Natural language processing can also help organise unstructured medical information, while automation can reduce repetitive administrative tasks. These capabilities are giving clinical trials services new ways to support faster analysis and more informed research decisions. Cloud-based platforms are strengthening the digital infrastructure used throughout clinical development. Centralised environments can bring study information together, improve access for authorised teams and support collaboration between research stakeholders working in different locations. Advanced analytics can further help identify emerging patterns, monitor study performance and highlight areas that may require attention. Strong data governance and cybersecurity will remain essential as clinical research becomes increasingly dependent on connected digital systems. The next phase of clinical research is likely to bring greater integration between artificial intelligence, advanced analytics, connected devices and digital health technologies. Digital biomarkers, remote measurement tools and predictive models could provide researchers with richer insights into patient responses and treatment outcomes. Such developments may also support more personalised approaches to study design and evidence generation, particularly as therapies become increasingly targeted. Europe is expected to remain an important environment for the adoption of these capabilities as life sciences companies seek more efficient ways to manage increasingly data-intensive development programs. Clinical trials services will likely evolve beyond traditional support functions toward more integrated research capabilities that combine scientific expertise, digital infrastructure, analytics and specialised operational knowledge. The continued maturation of these technologies could help clinical research teams generate stronger evidence while making development programs more responsive to the needs of modern drug development. ...Read more

Pharmaceutical Import Providers Must Establish the Legal Route

A hospital may locate a prescribed medicine abroad yet remain unable to purchase it. In Brazil, drugs lacking local registration or facing shortages can require different import arrangements depending on who is legally authorized to import and who will pay. Patient-directed orders and institutional procurement follow distinct rules. An incorrectly structured transaction can stall before customs clearance, regardless of supplier readiness. Before accepting a proposed delivery date, executives need to know whether a provider can establish a lawful import and payment structure. Regulatory routes shape the paperwork each participant can issue and the payment a bank will process. Personal-use imports in Brazil follow RDC 81/2008, while RDC 939/2024 sets operating authorization requirements for companies importing on behalf of third parties. The purchaser’s own regulatory status must also be checked. Foreign exchange introduces separate banking requirements. A provider that treats these decisions as clerical work after sourcing may leave a hospital with a prescription but no executable purchase. Contract terms must distinguish who holds regulatory responsibility from who coordinates the filings. Product availability alone does not establish a dependable supply channel. Institutions purchasing high-cost medicines need evidence of provenance that can withstand receipt checks and later review. Batch and expiration details must be traceable to certificates of analysis and origin issued at source. The supplier must also produce documentation acceptable to the importing country. A commercial invoice made out to the wrong party can delay an otherwise legitimate shipment. Buyers should establish who prepares shipping documents and who verifies consistency with the selected import arrangement. Temperature-sensitive therapies expose weaknesses between overseas dispatch and local receipt. Qualified packaging must maintain the required range, while a data logger captures conditions during transit. An acceptable reading at delivery does not replace the recorded excursion history. Sanitary inspections or customs holds can extend the interval before release, increasing pressure on the transfer into licensed storage when needed. A provider's contract should specify responsibility for courier coordination, customs brokerage, airport collection and custody records. A fast shipping estimate offers little assurance if ownership becomes unclear at handoff. “Medssey maintains a dossier for each operation and issues staged updates supported by filing and shipment references.” Court-ordered purchases impose a separate accounting burden. An institution may need to reconcile overseas settlement with the amount advanced, retaining customs and tax records for subsequent review. Status reports also affect staff time. An Anvisa filing number, air waybill, tracking link and revised delivery forecast allow buyers to distinguish a shipment awaiting regulatory release from one still moving internationally. Responsibility for exceptions should remain clear even when several outside providers participate. The closing record should reconcile expenditure rather than simply confirm delivery. Medssey structures medicine imports around the legally authorized importer and the permitted payment route before committing to execution. It starts from the prescription to verify the medicine's presentation and treatment duration, then checks supplier records and prepares documents for the applicable route. Its coordination covers foreign exchange, Anvisa filings, customs clearance and temperature-controlled transport with shipment data loggers when required. Medssey maintains a dossier for each operation and issues staged updates supported by filing and shipment references. For institutional and publicly funded transactions, it reconciles expenses against funds received. This service model addresses Brazilian hospitals and public health agencies procuring prescribed medicines under court orders, where the payer and legal importer must be identified before shipment. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

APAC Vaccine Research and Development: Scientific Progress and Opportunities

Science-based research is helping improve accuracy in preventive medicine since the life sciences sector is increasingly focusing on immunity and public health concerns. In the Asia-Pacific (APAC) region, innovative vaccine researchers and developers play an important role in strengthening disease prevention through research-driven approaches that support targeted immunization strategies and improved protection against infectious diseases. Increased cooperation between scientific institutions, biotechnologists and health agencies will enhance scientific knowledge in the field, which will prove useful to society. Such actions play an important role in decreasing the spread of diseases and ensuring that people remain healthy by avoiding preventable diseases and supporting healthier populations. Pioneering Scientific Breakthroughs in Next-Gen Vaccine Development Development in molecular biology is bringing increased levels of accuracy in vaccine design using advanced techniques of antigen engineering. Messenger RNA (mRNA) technology enables cells to produce specific proteins that stimulate immune responses, while self-amplifying RNA platforms offer the potential to achieve effective antigen expression at lower doses. Improved lipid nanoparticle formulations further support the efficient delivery of genetic material into cells. The study of structural biology and computational modeling is increasingly facilitating the discovery of potential vaccine targets. High-resolution visualization allows researchers to gain a better understanding of the structure of a pathogen and discover key molecules. Artificial intelligence and machine learning help predict the structure of proteins, analyze biological data and identify suitable antigens, especially in organisms with high rates of genetic mutation. New vaccine modalities are increasing the scope of research opportunities within the APAC region's life sciences sector. The use of nanoparticles allows presenting multiple antigens to the immune system, which may help enhance immune responses. Mucosal vaccines are being tested on their potential to induce immune responses at respiratory portals and multivalent vaccines seek to protect against multiple strains of pathogens using a single vaccine formulation. Regulatory Environment and Clinical Development Challenges The regulatory requirements will continue to play an important part in the decision-making process of the companies manufacturing vaccines due to the fact that the regulatory authorities need extensive evidence in terms of safety and efficacy. The authorities in the APAC region follow different evaluation procedures, documentation standards and submission requirements, creating additional complexities for companies seeking approvals in multiple markets. Early engagement with regulatory agencies and well-structured compliance strategies can help streamline submissions and minimize avoidable delays. Clinical development offers additional issues, concerning the recruitment of appropriate volunteers and the maintenance of balanced populations during vaccine studies. Disparities in the rate of illness and in the demographics and health care systems can affect the conduct of research studies. Establishing clear eligibility criteria, strengthening trial site coordination and implementing effective participant monitoring practices can improve study execution while maintaining ethical standards and data reliability. The manufacture of compliance brings another dimension of complexity to the development process of vaccines. Maintaining batch consistency, validating the manufacturing process and complying with good manufacturing practice requirements call for stringent quality control measures. Unforeseen production changes can have an impact on the timeline for development and the regulatory review process. Comprehensive quality management systems, standardized testing procedures and thorough process validation help manufacturers address these challenges while maintaining product integrity. Future Prospects and Emerging Opportunities The next stage of the vaccine development process will be concentrated on developing prevention techniques against diseases for which there is no vaccination yet. Conditions such as HIV, tuberculosis and malaria present opportunities for scientific advancement, particularly as researchers seek to address their complex biological characteristics. Progress in these areas could expand the scope of vaccination programs and strengthen long-term disease management strategies. The creation of personalized vaccines constitutes yet another domain where the life sciences industry holds tremendous promise. Progress in the field of immunogenomics may assist scientists in comprehending how genetic variation affects personal reactions to vaccinations. The results of such studies may be useful in creating new vaccination approaches and better vaccines for people who are susceptible to diseases due to poor immunity. Investments in developing research capabilities will also result in further opportunities in the APAC region. Expanding biopharmaceutical development facilities, strengthening regional supply networks and improving access to specialized scientific expertise could support greater participation in the global vaccine industry. These developments may also encourage local production capabilities and reduce dependence on external supply sources. Innovative vaccine research and developer activities are likely to benefit from increasing interest in pandemic preparedness and rapid-response vaccine development. Adaptable manufacturing capability, the retention of prototypes for vaccines and enhanced surveillance of pathogens could better prepare against such infectious disease threats in the future. Such initiatives are expected to shape future industry priorities, supporting a more responsive and resilient vaccine development landscape. ...Read more

Specials

Connecting Scientific Innovation with Commercial Strategy